Hansoh Pharma (03692): B7-H3 targeted antibody-drug conjugate HS-20093 approved as breakthrough therapy for castration-resistant prostate cancer.
Hanson Pharmaceuticals (03692) announced that on April 29, 2026, the Group's self-developed B7-H3 targeted antibody-drug conjugate (ADC) injection HS-20093 has been approved by the China National Medical Products Administration (NMPA) as a breakthrough therapeutic drug, with the intended indication for advanced castration-resistant prostate cancer that has previously received novel hormonal therapy and docetaxel chemotherapy.
Hansoh Pharma (03692) announced that on April 29, 2026, the group's self-developed B7-H3 targeted antibody-drug conjugate (ADC) injection HS-20093 has been approved by the National Medical Products Administration (NMPA) of China as a breakthrough therapy. It is intended for the treatment of late-stage castration-resistant prostate cancer that has previously received new hormonal therapy and taxane chemotherapy.
Related Articles
ELIFE Holdings (00223) completed the placement of a total of 271 million shares, raising approximately 27.1 million Hong Kong dollars.
GigaDevice Semiconductor Inc. (03986) released its first quarter results with a net profit attributable to shareholders of approximately 1.461 billion yuan, a year-on-year increase of 522.79%.
ANDRE JUICE (02218) announces its first quarter performance with a net profit attributable to the parent company of 72.70 million RMB, a decrease of 15.52% compared to the same period last year.
ELIFE Holdings (00223) completed the placement of a total of 271 million shares, raising approximately 27.1 million Hong Kong dollars.
GigaDevice Semiconductor Inc. (03986) released its first quarter results with a net profit attributable to shareholders of approximately 1.461 billion yuan, a year-on-year increase of 522.79%.
ANDRE JUICE (02218) announces its first quarter performance with a net profit attributable to the parent company of 72.70 million RMB, a decrease of 15.52% compared to the same period last year.
RECOMMEND
